H.C. Wainwright Reiterates a Buy Rating on Opko Health (OPK), Keeps the PT at $3

Opko Health Inc. (NASDAQ:OPK) is one of the 13 Stocks Under $5 With High Upside Potential. On May 1, analyst Yi Chen of H.C. Wainwright reiterated a Buy rating on Opko Health Inc. (NASDAQ:OPK), retaining the price target of $3.00. Despite mixed fiscal Q1 2025 results, the rating was supported by future prospects and strategic developments undertaken by the company.

Is Opko Health Inc. (OPK) the Best Nasdaq Stock Under $5 to Buy?

A doctor in scrubs discussing a patient’s test results with a small group of concerned family members.

Although Opko Health Inc. (NASDAQ:OPK) reported a decline in consolidated total revenue to $149.9 million in fiscal Q1 2025, the analyst sees potential in its future guidance. Management expects total revenue for full year 2025 to be in the $675-685 million range.

In addition, Chen expects the pending transaction with Labcorp to close in the third quarter of 2025, thereby increasing profitability and streamlining BioReference’s operations. He further stated that a significant factor lending Opko Health Inc. (NASDAQ:OPK) a prominent position in the obesity and metabolic disorders treatment space is the advancement of an innovative oral dual agonist GLP-1/glucagon peptide. The company has plans to file an IND application later in the year.

Opko Health Inc. (NASDAQ:OPK) is a biopharmaceutical and diagnostics company that provides healthcare services. Its operations are divided into the Diagnostics and Pharmaceuticals segments.

While we acknowledge the potential of OPK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.